Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis
Authors:
- 24 July 2020
- journal article
- review article
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (5) , 650-657
Abstract
Background Patients with multiple myeloma (MM) have increased risks of venous thromboembolism (VTE) and arterial thromboembolism (ATE). The risk of thrombosis differs among different treatment regimens. It is unknown if daratumumab could affect thrombosis risk. Methods A comprehensive search was conducted until April 2020. Events of VTE, including pulmonary embolism and deep venous thrombosis, as well as events of ATE, including acute ischemic stroke and myocardial infarction, were extracted from trials. In addition, events of thrombocytopenia and gastrointestinal (GI) bleeding were also extracted. Results Six trials were included in the meta-analysis. Daratumumab was associated with a lower risk of VTE compared with non-daratumumab regimen (Risk ratio [RR], 0.60; 95% confidence interval [CI], 0.40–0.91). The risk of ATE had no significant difference (RR, 0.80; 95% CI, 0.48–1.33). Daratumumab was also associated with a trend of higher risk of Grade 3/4 thrombocytopenia (RR, 1.14; 95% CI, 0.94–1.38), while the risk of GI bleeding was not significantly different (RR, 1.32; 95% CI, 0.38–4.65). Conclusion Daratumumab is associated with lower risk of VTE in clinical trials.Keywords
This publication has 25 references indexed in Scilit:
- Thromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic reviewThrombosis Research, 2016
- Venous Thromboembolism in Patients With Thrombocytopenia: Risk Factors, Treatment, and OutcomeClinical and Applied Thrombosis/Hemostasis, 2015
- Methods to estimate the between‐study variance and its uncertainty in meta‐analysisResearch Synthesis Methods, 2015
- Thrombosis in multiple myeloma (MM)Hematology, 2012
- Critical Role for CD38-mediated Ca2+ Signaling in Thrombin-induced Procoagulant Activity of Mouse Platelets and HemostasisJournal of Biological Chemistry, 2011
- Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2011
- Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based studyBlood, 2010
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- Uncertainty in heterogeneity estimates in meta-analysesBMJ, 2007
- Malignancies, Prothrombotic Mutations, and the Risk of Venous ThrombosisJAMA, 2005